Abstract: The purpose of the present invention is to provide a cell creation method that enables a reduction in cost and time, that is highly safe, and that has great potential for being industrially applied. Provided by the present invention is a method for inducing differentiation of pluripotent cells in vitro into cells having a same phenotype and function as information-presentation cells, the method comprising co-culturing pluripotent cells or a cellular fraction having said pluripotent cells concentrated therein, together with damaged cells or dead cells derived from information-presentation cells, or together with a portion of the damaged cells or dead cells derived from information-presentation cells.

Abstract: Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease characterized by the progressive loss of motor neurons. Muse cells are endogenous reparative pluripotent-like stem cells distributed to various tissues. Once intravenously injected, such cells, upon sensing sphingosine-1-phosphate produced by damaged cells, settle selectively on damaged sites, and after homing, can exhibit multiphase effects including natural differentiation into tissue-protecting and tissue-reconstructing cells. In the present invention, with G93A-Tg mice serving as an ALS model, human Muse cells injected intravenously successfully homed into the lumbar cord, mainly at the pia mater and the lower white matter, and expressed glial-like forms and GFAP. Meanwhile, no such homing or differentiation was observed in the case of human mesenchymal stem cells (MSCs), and, rather, MSCs were found distributed to the lungs.

Abstract: The high-potential pluripotent stem cells of the present invention not only have characteristics of conventional Muse cells, namely, are capable of differentiating into any embryonic tissue serving as all cells constituting the body, but also are capable of differentiating into any extraembryonic tissue cells such as placenta and/or germline cells, namely, have differentiation capacities close to totipotency. Thus, the high-potential pluripotent stem cells not only allow for conventional regenerative therapies of various diseases which cause any damage in constitution of the body, but also are capable of differentiating into any extraembryonic tissue cells such as placenta, and thus can allow any damaged sites in such any extraembryonic tissue to be re-constituted, resulting in improvement or restoring of the function of such any damaged sites, and can be applied to a new field of regenerative therapy, for example, can be used in reproductive therapies such as fertility therapy.

Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

Abstract: There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.

Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

Abstract: Provided is a cell product for treating myocarditis, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.

Abstract: A method for treating or repairing osteochondral damage in a subject in need thereof, including administering to the subject a cell preparation comprising pluripotent stem cells positive for SSEA-3 isolated from a body mesenchymal tissue or cultured mesenchymal cells. The pluripotent stem cells have all of the following properties: (i) CD105-positivity; (ii) low or absent telomerase activity; (iii) having ability to differentiate into any of three germ layers; (iv) absence of demonstration of neoplastic proliferation; and (v) self-renewal ability. The pluripotent stem cells are administered at 1×103 cells to 2×107 cells as individual.

Abstract: A cell product for prevention and/or treatment of vascular disorders such as aortic aneurysm, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell (Muse cell).

Abstract: This disclosure describes efficient methods for separating desired populations of cells, including Multilineage-Differentiating Stress-Enduring (MUSE) cells. Also described are the methods for isolating and enriching MUSE cells through a sorting, expanding, and re-sorting procedure. The enriched cells or cell populations can be used for treating cancer, repairing various tissues, and treating various degenerative or inherited diseases.

Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.

Abstract: A cell product may be used for treating a peripheral blood flow disorder, and the cell product may include an SSEA-3-positive pluripotent stem cells (Muse cells) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. The peripheral blood flow disorder is preferably a peripheral arterial disease, more preferably chronic arterial obstruction in a limb.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: The purpose of the present invention is to provide a novel medicinal use in regeneration medicine, said medicinal use comprising using pluripotent stem cells (Muse cells). Provided is a cell preparation for treating skin ulcer, said cell preparation comprising SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue of a living organism or cultured mesenchymal cells. The cell preparation according to the present invention is based on such mechanism of skin tissue regeneration that, when the Muse cells are administered to a skin ulcer site of a subject suffering from the aforesaid disease, the Muse cells differentiate into skin-constituting cells.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: An agent for promoting migration of pluripotent stem cells containing an extract from inflamed tissues inoculated with vaccinia virus. An extract from inflamed tissues inoculated with vaccinia virus promotes migration of Muse cells. Thus, the agent for promoting migration of pluripotent stem cells for various diseases to which migration of pluripotent stem cells may have an advantageous effect.

Abstract: Multilineage-differentiating stress enduring (Muse) cells are stage-specific embryonic antigen-3 (SSEA-3) positive cells that exist in mesenchymal stem cell (MSC) populations. Muse cells have the pluripotency to differentiate into all germ layers as embryonic stem cells. The purpose of the present study is to investigate the efficacy of Muse cell transplantation for repairing osteochondral defects. Muse cells were isolated from human bone marrow MSCs. As osteochondral defects, the patellar grooves of immunodeficient rats were injured. Next, cells were injected into the mice so that the animals were divided into the following 3 groups: a control group to which PBS was injected; a non-Muse group to which 5×104 SSEA-3 negative non-Muse cells were injected; and a Muse group to which 5×104 SSEA-3 positive Muse cells were injected.

Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

Abstract: Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.